Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroimaging Predictors of Antidepressant Treatment Outcome
NCT02000726Phase 2Withdrawn
- Sponsor
- University of Michigan
- Start
- Jul 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of citalopram in major depressive disorder (MDD), sponsored by University of Michigan. Primary endpoint: Blood-oxygen-level dependent responses during the Real-Time Neurofeedback Task. Planned start Jul 2013; status: withdrawn.
02
Drugs
citalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02000726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02000726.